secwatch.observer — SEC 8-K summary
======================================

Issuer:     Baudax Bio, Inc. (—)
CIK:        0001780097
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001193125-23-149303
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Baudax Bio receives Nasdaq delisting notice for failing to meet stockholders' equity requirement
--------------------------------------------------------------------------------

- Nasdaq determined Baudax Bio did not meet the $2.5M minimum stockholders' equity requirement for continued listing.
- Company's extension to regain compliance expired May 15, 2023; proposed transactions not completed.
- Trading of common stock (BXRX) may be suspended on May 26, 2023 unless Company appeals.
- Company intends to request a hearing before the Nasdaq Hearings Panel to present a compliance plan.
- If delisted, ability to raise capital and stock price could be materially impaired.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523149303/0001193125-23-149303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523149303/d465022d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-149303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer